Stay updated with breaking news from Bcli. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
StockNews.com assumed coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI – Free Report) in a research report sent to investors on Thursday morning. The firm issued a hold rating on the biotechnology company’s stock. Separately, Maxim Group cut Brainstorm Cell Therapeutics from a buy rating to a hold rating in a research report on Thursday, […]
StockNews.com assumed coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report) in a research report issued on Tuesday. The brokerage set a “hold” rating on the biotechnology company’s stock. Separately, Maxim Group downgraded Brainstorm Cell Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, September 28th. […]
BrainStorm Cell Therapeutics Inc. shares fell 56% premarket on Thursday after advisors to the U.S. Food and Drug Administration on Wednesday gave a...
A U.S. Food and Drug Administration advisory committee voted against a treatment from BrainStorm Cell Therapeutics for amyotrophic lateral sclerosis, or ALS.
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Rating)’s share price passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $2.26 and traded as high as $2.40. Brainstorm Cell Therapeutics shares last traded at $2.32, with a volume of 301,181 shares changing […]